Detection of anti-premembrane antibody as a specific marker of four flavivirus serocomplexes and its application to serosurveillance in endemic regions Guan-Hua Chen^{a†}, Yu-Ching Dai^{a†}, Szu-Chia Hsieh^a, Jih-Jin Tsai^{b,c,d}, Ava Kristy Sy^e, Mario Jiz^f, Celia Pedroso^g, Carlos Brites^g, Eduardo Martins Netto^g, Phyllis J. Kanki^h, Danielle R. D. Saundersⁱ, Dana L. Vanlandingham^j, Stephen Higgs^j, Yan-Jang S. Huang^j, Wei-Kung Wang^{a*} ^aDepartment of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns

8 School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA; ^bTropical Medicine

9 Center, ^cDivision of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical

10 University Hospital, ^dSchool of Medicine, College of Medicine, Kaohsiung Medical University,

11 Kaohsiung, Taiwan; ^eNational Reference Laboratory for Dengue and Other Arbovirus, Virology

12 Department, and ^fImmunology Department, Research Institute for Tropical Medicine, Muntinlupa

13 City, Philippines; ^gLAPI-Laboratório de Pesquisa em Infectologia-School of Medicine, Federal

14 University of Bahia, Salvador, Brazil; ^hDepartment of Immunology and Infectious Diseases,

15 Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA; ⁱDepartment of

16 Biology, United States Air Force Academy, USA; ^jBiosecurity Research Institute and Department

17 of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University,

18 Kansas, USA

19 [†]These authors contribute equally to this work.

20 Contact: Wei-Kung Wang, wangwk@hawaii.edu, Department of Tropical Medicine, Medical

21 Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at

22 Manoa, Honolulu, HI 96813, USA

23 Keywords: Yellow fever virus, flavivirus, antibody, premembrane protein, serosurveillance

25 ABSTRACT

In the past few decades, several emerging/re-emerging mosquito-borne flaviviruses have 26 27 resulted in disease outbreaks of public health concern in the tropics and subtropics. Due to crossreactivities of antibodies recognizing the envelope protein of different flaviviruses, 28 serosurveillance remains a challenge. Previously we reported that anti-premembrane (prM) 29 antibody can discriminate between three flavivirus infections by Western blot analysis. In this 30 study, we aimed to develop a serological assay that can discriminate infection or exposure with 31 flaviviruses from four serocomplexes, including dengue (DENV), Zika (ZIKV), West Nile 32 (WNV) and yellow fever (YFV) viruses, and explore its application for serosurveillance in 33 flavivirus-endemic countries. We employed Western blot analysis including antigens of six 34 flaviviruses (DENV1, 2 and 4, WNV, ZIKV and YFV) from four serocomplexes. We tested 35 serum samples from YF-17D vaccinees, and from DENV, ZIKV and WNV panels that had been 36 confirmed by RT-PCR or by neutralization assays. The overall sensitivity/specificity of anti-prM 37 38 antibodies for DENV, ZIKV, WNV, and YFV infections/exposure were 91.7%/96.4%, 91.7%/99.2%, 88.9%/98.3%, and 91.3%/92.5%, respectively. When testing 48 samples from 39 Brazil, we identified multiple flavivirus infections/exposure including DENV and ZIKV, DENV 40 and YFV, and DENV, ZIKV and YFV. When testing 50 samples from the Philippines, we 41 detected DENV, ZIKV, and DENV and ZIKV infections with a ZIKV seroprevalence rate of 42 10%, which was consistent with reports of low-level circulation of ZIKV in Asia. Together, 43 these findings suggest that anti-prM antibody is a flavivirus serocomplex-specific marker and 44 can be employed to delineate four flavivirus infections/exposure in regions where multiple 45 flaviviruses co-circulate. 46

47 Introduction

In the genus *Flavivirus* of the family *Flaviviridae*, there are several mosquito-borne viruses 48 49 causing significant diseases in humans; including the four serotypes of dengue virus (DENV) in the DENV serocomplex, West Nile virus (WNV) and Japanese encephalitis virus (JEV) in the 50 JEV serocomplex, Zika virus (ZIKV), and yellow fever virus (YFV) as a single member [1]. 51 52 The four serotypes of DENV (DENV1-DENV4) continue to be a global public health threat in tropical and subtropical regions [2-4]. It has been estimated that approximately 390 million 53 DENV infections occur annually worldwide [2-4]. Most DENV infections are inapparent or 54 subclinical with about 25% leading to clinical disease including dengue, dengue with warning 55 signs, and severe dengue [2-4]. Of the DENV vaccine candidates that have completed different 56 phases of clinical trials, Dengvaxia, a chimeric yellow fever-dengue tetravalent vaccine, was the 57 first DENV vaccine licensed [5]. As DENV-seronegative children receiving Dengvaxia were 58 reported to have a higher risk for hospitalization and severe dengue during subsequent DENV 59 60 infection, Dengvaxia was recommended for DENV-seropositive individuals aged 9-45 years [5-7]. Pre-vaccination screening strategies using assays with high sensitivity and specificity have 61 been proposed, highlighting the need for reliable serological tests to determine DENV serostatus 62 63 in flavivirus-endemic regions [8].

Three additional flaviviruses, YFV, WNV, and ZIKV were also included in this research. In sub-Sahara Africa and tropical America, YFV is endemic with an estimate of 200,000 severe cases and up to 60,000 deaths per year [9,10]. The recent outbreaks in Angola and the Democratic Republic of the Congo, followed by the outbreaks in Brazil and Nigeria, suggest that YFV has expanded to new areas to affect large populations in South America and Africa [9,10]. First isolated in Uganda in 1937, WNV caused human cases and outbreaks in Africa and Europe;

since 1999 WNV has spread throughout the continental U.S. and to Canada and Mexico [1,11]. 70 The reports of increased incidence in the geographic distribution of WNV and travel-related 71 72 WNV cases posed new challenge of serosurveillance for flaviviruses [11,12]. ZIKV, first isolated in Uganda in 1947, was associated with relatively few human cases until the outbreaks 73 on Yap Island in 2007 and French Polynesia in 2013-2014. The subsequent explosive spread in 74 75 the Americas since 2015 has resulted in ~800,000 suspected or confirmed cases [13,14]. The association of ZIKV with microcephaly and other birth defects, known as congenital Zika 76 syndrome (CZS), has raised global public health concern [13-15]. Despite a decline in ZIKV 77 transmission since late 2017, the specter of its re-emergence and CZS in the endemic regions 78 remains. 79

Knowing the seroprevalence rates of flaviviruses is critical to our understanding of the 80 epidemiology and transmission dynamics of flaviviruses and critical for the development of 81 intervention strategies. In addition, information about DENV serostatus can be used to evaluate 82 83 DENV vaccine efficacy and determine if an individual would benefit from Dengvaxia and/or other vaccine candidates. Due to the presence of mosquito vectors in the regions, there is 84 considerable geographic overlap in the distribution of different flaviviruses, such as DENV, JEV 85 86 and ZIKV in Southeast Asia; DENV, YFV and ZIKV in South America; and DENV, YFV, WNV and ZIKV in sub-Sahara Africa. Our knowledge about the effects of prior immunity to one 87 88 flavivirus on disease outcome of infection with another flavivirus in humans was primarily based 89 on cohort studies. It has been reported that preexisting JEV neutralizing antibodies increased symptomatic DENV infection in Thailand [16]. Since the ZIKV outbreak during 2015–2017, 90 91 two studies reported that prior DENV infection was associated with reduced risk of symptomatic 92 ZIKV infection [17,18]. Another study showed that one prior ZIKV infection or one prior DENV

followed by one ZIKV infection increased the risk of subsequent symptomatic DENV2 infection 93 and severe disease, whereas a prior ZIKV with two or more DENV infections had a protective 94 effect [19], underscoring the importance of reliable serological tests that can discriminate DENV, 95 ZIKV and/or other flavivirus infections to improve our understanding of the complex 96 interactions between DENV, ZIKV and/or other flaviviruses in endemic regions. 97 98 Present on the surface of flavivirus particles, the envelop (E) protein is the major target of neutralizing antibodies and vaccine development [1,20]. The ectodomain of the E protein 99 100 contains 3 domains; the fusion loop (FL) is located at the tip of domain II and contains several 101 highly conserved residues [1,20]. The premembrane (prM) protein, a glycoprotein of ~19 kDa, is cleaved by furin or furin-like protease to precursor (pr) and membrane (M) proteins during 102 maturation in the *trans*-Golgi [1,20]. Several serological tests have been developed based on the 103 E protein including recombinant E protein, inactivated virions, or virus-like particles (VLPs) 104 [20-23]. Due to cross-reactivity of anti-E antibodies to different flaviviruses, E protein-based 105 serological tests cannot discriminate different flavivirus infections [20,23-27]. Nonstructural 106 protein 1 (NS1)-based serological tests including enzyme-linked immunosorbent assay (ELISA), 107 blockade of binding ELISA, and microsphere immunoassay have shown improved specificity 108 109 [28-32]. However, the reduced durability of anti-NS1 antibodies could be a challenge for seroprevalence studies. 110 111 The plaque reduction neutralization test (PRNT) is considered the gold standard serological 112 test and has been employed to confirm different flavivirus infections in serosurveillance and seroprevalence studies [1,23]. For individuals experiencing a single flavivirus infection, it 113

identifies monotypic neutralizing antibodies against a single flavivirus, such as neutralizing

antibody against one DENV serotype or ZIKV in individuals with primary DENV (pDENV) or

primary ZIKV (pZIKV) infection, respectively [23,33-35]. For individuals experiencing multiple
flavivirus infections, it reveals multitypic neutralizing antibodies against multiple flaviviruses,
such as two or more DENV serotypes and/or other flaviviruses in individuals with secondary
DENV (sDENV) infection [23,33-35]. Therefore, multitypic neutralizing antibodies were
interpreted as unspecified flavivirus infections and cannot discriminate between the flaviviruses
experienced in the past such as sDENV infection versus previous DENV and ZIKV
(DENV+ZIKV) infections [23].

Previously, we employed Western blot analysis using an antigen panel of six flavivirus-123 infected cell lysates (DENV1-4, WNV and ZIKV) from three serocomplexes to test different 124 panels with known flavivirus infections and reported that anti-prM antibodies can discriminate 125 between DENV, ZIKV and WNV infections [36]. Whether or not this assay can be extended to 126 include other flaviviruses such as YFV and applied to serosurveillance in flavivirus-endemic 127 regions remains unanswered. In this study, we aimed to develop a serological test that can 128 129 discriminate infection of flaviviruses from four serocomplexes including DENV, ZIKV, WNV and YFV, and examine samples collected from serosurveillance in the Philippines and Brazil. 130 The underlying hypothesis was that detection of anti-prM antibody can discriminate infections 131 132 caused by four flavivirus serocomplexes. We found anti-prM antibody is a specific marker for four flavivirus serocomplexes. 133

134 Materials and methods

135 Human samples

136 This study was approved by the Institutional Review Boards (IRBs) of the University of Hawaii

- 137 (CHS#17568, 2022-00201, 2021-00947), the Kaohsiung Medical University Hospital, Taiwan
- 138 (KMUH-IRB-960195, KMUH-IRB-E[I]-20170185), and the Research Institute for Tropical
- 139 Medicine (RITM), Philippines (2019-042). The numbers, sampling time, sources and
- 140 confirmation methods of different panels of serum or plasma samples with known flavivirus
- 141 infections or vaccination are summarized in Table S1. Samples from reverse transcription-
- 142 polymerase chain reaction (RT-PCR)-confirmed Zika cases including previously DENV-naïve
- 143 (n=18) or DENV-exposed (n=13), designated as pZIKV or DENV+ZIKV panels respectively,

144 were collected between July and March 2017 from the Pediatric Dengue Cohort Study and the

- 145 Pediatric Dengue Hospital-based Study in Managua, Nicaragua [37,38]. The studies were
- approved by the IRBs of the University of California, Berkeley, and the Nicaraguan Ministry of
- 147 Health. Samples from a ZIKV study in Salvador, an epicenter of ZIKV outbreak in Brazil, were
- 148 confirmed by microneutralization tests (to ZIKV and DENV) as pZIKV (n=5), DENV+ZIKV
- 149 (n=12), pDENV (n=4), and sDENV (n=21) panels as described previously [39]. The study was
- approved by Approved the Comitê de Ética em Pesquisa da Maternidade Climério de
- 151 Oliveira/UFBA, Brazil (CAAE: 25336819.3.0000.5543/4.691.233, 2019). Samples (n=18) from
- 152 blood donors, who tested positive for WNV transcription-mediated amplification (TMA), IgM
- and IgG antibodies, were designated as the WNV infection panel, were provided by the
- American Red Cross at Gaithersburg, Maryland [40]. Samples from a DENV seroprevalence
- study in Kaohsiung, Taiwan were confirmed by a microneutralization test (to DENV) as pDENV
- 156 (n=17), sDENV (n=29) or DENV-naive (n=29) [41,42]; the sampling time was available based

157	on questionnaires from study participants. Samples of YF-17D vaccinees were from the US
158	(n=10) and Brazil (n=9) based on history of YF-17D vaccination [43]; samples from non-human
159	primates (NHP) receiving YF-17D vaccine (n=4) were from the BEI Resources (NIAID, NIH).
160	Additionally, samples from 50 participants (aged 2 to 56 years) collected between January 2018
161	and May 2019 from a fever surveillance program at the RITM, Philippines were included as a
162	test panel [43]. These were non-Dengvaxia recipients and presented with symptoms suspected of
163	dengue; blood samples were negative by DENV RT-PCR or DENV IgM-capture ELISA.
164	Another panel of samples (n=48) of suspected ZIKV cases (aged 15-70 years) collected between
165	2015 and 2016 from the ZIKV study in Salvador, Brazil was included as a second test panel [31].
166	Western blot analysis
167	Uninfected (mock) Vero cells and Vero cells infected with DENV1 (Hawaii strain), DENV2
168	(NGC strain), DENV4 (H241 strain), ZIKV (PRVABC59 strain), WNV (NY99 strain) or YFV
169	(17D vaccine strain) were lysed with NP-40 lysis buffer (1% NP-40, 50 mM Tris pH 8.0, 150
170	mM NaCl, 2 mM EDTA, and 1 mM Na ₃ VO ₄) when 50% of cells were found to have cytopathic
171	effects. The cell lysates were loaded into two half-gels (seven wells each) and subjected to SDS-
172	12% polyacrylamide gel electrophoresis under non-reducing condition (2% SDS, 0.5 M Tris pH
173	6.8, 20 % glycerol, 0.001 % bromophenol blue, final) [24,36], followed by transfer to
174	nitrocellulose membrane (Trans-Blot Turbo RTA Midi Transfer Kit, BioRad), hybridization with
175	human serum/plasma samples (1:200 dilution) or mouse monoclonal antibody (mAb) and
176	secondary antibody (IRDye® 800CW-conjugated goat anti-human IgG at 1:10000). The signals
177	were detected by Li Cor Odyssey classic (LiCor Biosciences) and analyzed by Image Studio
178	software with both short and long exposures [36,42]. Each gel was read independently by two
179	researchers with the results summarized in Supplementary Table 2. To test the stability of the

assay, the half-membranes after blocking step were stored in the -20°C freezer until use for
hybridization to serum/plasma.

182 **Expression of YF-17D prM/E proteins**

183 293T cells ($1x10^5$ cells) were transfected with 10 µg of a plasmid expressing the prM/E proteins

of YF-17D. At 48 h, cells were washed with 1X PBS and treated with 1% NP40 lysis buffer,

followed by centrifugation at $20,000 \times \text{g}$ at 4°C f or 30 min to obtain cell lysates for Western blot analysis probed with human dengue-immune serum as described above [24,36].

187 DENV FL-VLP IgG ELISA

188 IgG ELISA using DENV1 FL-mutated VLPs was described previously [44]. Briefly, DENV1

189 FL-mutated VLPs (containing W101A and F108A mutations) were coated onto 96-well plates at

¹⁹⁰ 4°C overnight, followed by blocking (StartingBlock blocking buffer, Thermo Scientific,

191 Waltham, MA) at room temperature for 1 h, incubation with primary antibody (serum or plasma

at 1:400 dilution) at 37°C for 2 h, wash with washing buffer (0.5% Tween-20 in 1X PBS) 4

times, incubation with secondary antibody (anti-human IgG conjugated with horseradish

194 peroxidase [HRP] at 1:10,000 dilution, Jackson Immune Research Laboratory, West Grove, PA)

at 37°C for 1 h, and wash with washing buffer 6 times [40,44]. After incubation with

tetramethylbenzidine substrate (Thermo Scientific, Waltham, MA) at room temperature for 15

197 min and stop solution, the OD at 450 nm was read with a reference wavelength of 630 nm. Each

198 ELISA plate contained two positive controls (OD higher than 1; two confirmed-DENV samples),

199 four negative controls (DENV-naïve sera or plasma), and test samples (all in duplicate). For

200 comparison between plates, the relative OD (rOD) values were calculated by the OD values

divided by the mean OD value of one positive control (OD close to 1) in the same plate. The

202 cutoff rOD was defined by the mean rOD value of negatives plus 12 standard deviations, which

203 gave a confidence level of 99.9% from 4 negatives [45]. Each ELISA was performed in
204 duplicate.

205 *Microneutralization test*

206 Microneutralization tests were performed as described previously [39,42]. Briefly, two-fold

serial dilutions of serum were mixed with 50 focus-forming units of DENV1 (Hawaii), DENV2

208 (NGC), DENV3 (CH53489), DENV4 (H241), ZIKV (PRVABC59), or YFV (YF-17D) at 37°C

for 1 h; the mixtures were added to each well of 96-well plate which was pre-seeded with Vero

cells (3 x 10^4 cells per well) one day prior to infection. This was followed by incubation at 37° C

for 48-70 h, removal of medium, fixation [39,42], mouse mAb 4G2 and secondary antibodies

212 (IRDye® 800CW-conjugated goat anti-mouse IgG and DRAQ5[™] fluorescent probe at 1:10000).

213 The signals (800 nm/700 nm fluorescence) were detected using a LiCor Odyssey imager (LiCor

214 Biosciences) and analyzed by Image Studio to determine percent neutralization at different

concentrations and 90% neutralization (NT₉₀) titers [39,42].

216 Statistical analysis

The sensitivity, specificity and 95% confidence intervals (CI) were calculated by Excel. The
two-tailed Fisher's exact test and two-tailed Mann-Whitney test were used to compare
categorical and quantitative variables, respectively, between two groups (GraphPad Prism 6).
The positive, negative and overall agreements and kappa assessment were calculated by the
SPSS 20.

222 Results

223 Antibody response following YF-17D vaccination

224 The antigen panel in Western blot analysis included lysates derived from Vero cells infected with six flaviviruses (DENV1, 2 and 4, WNV, ZIKV and YF-17D vaccine strain) from four 225 serocomplexes. The control panels with known flavivirus infections or vaccination included 226 227 serum or plasma samples from YF-17D vaccinees (YF-17D panel), RT-PCR-confirmed ZIKV cases (pZIKV and DENV+ZIKV panels), TMA-confirmed WNV infection (WNV panel), and 228 229 neutralization-confirmed DENV infection or DENV-naïve participants (pDENV, sDENV and DENV-naïve panels) from a DENV seroprevalence study (Table S1). We first examined antibody 230 response in two vaccinees ~3 months following YF-17D vaccination by Western blot analysis. 231 Each lane contained individual viral proteins presumably in equal molar ratio except for those 232 structural proteins released with virions; a previously described flavivirus group-reactive mouse 233 mAb FL0232, which recognized E proteins (DENV1-4, ZIKV, WNV and YFV) equally well, was 234 235 used to verify comparable amounts of loaded antigens (Figure 1(C)) [23,36]. DENV3-infected cell lysate was not included due to high amino acid homology between DENV3 and DENV1 236 (compared with DENV2 or DENV4) and the convenience of loading seven lanes in a half 237 238 membrane. As shown in Figure 1(A), anti-E antibodies cross-reactive to all six flaviviruses tested, and anti-NS1 and anti-prM antibodies recognizing YFV only were observed. A similar trend was 239 240 observed in 17 other samples, although some recognized YFV E protein only (Table S2). Notably, 241 the YFV prM protein migrated at a slower rate than the prM proteins of other flaviviruses 242 (DENV1, 2 and 4, WNV and ZIKV) tested, corresponding to the size of a 23 kDa protein; this was confirmed by the size of prM protein expressed by a YF-17D prM/E plasmid (Figure 1(B)). 243 244 We next examined samples from three NHPs receiving YF-17D vaccine (1 to 18 months, pooled

sera); anti-E antibodies recognizing YFV and/or other five flaviviruses tested together with anti-245 NS1 and anti-prM antibodies recognizing YFV only were observed (Figure 1(D)). As a 246 247 comparison, no protein band corresponding to E, NS1 or prM protein was recognized by a DENV-naive sample (Figure 1(E), Table S2). Different viral protein bands recognized by samples 248 from 19 YF-17D vaccinees and four NHPs receiving YF-17D vaccine are summarized in Table 1. 249 250 Anti-prM antibodies can discriminate four flavivirus infections or exposure We further examined antibody response following DENV infection (Table S1). The results of 251 three samples each from the pDENV panel and sDENV panel were shown in Figures 1(F) and 252 1(H), respectively. Anti-E antibodies cross-reactive to all six flaviviruses, anti-NS1 antibodies to 253 one to three DENV serotypes with cross-reactivity to ZIKV or YFV, and anti-prM antibodies to 254 DENV without cross-reactivity to ZIKV, WNV or YFV were found in both panels, including 255 samples collected more than 29 years after infection (Figures 1(F) and 1(H)). A similar pattern of 256 viral protein recognition was observed in other samples of the pDENV and sDENV panels (Table 257 258 S2), except that the sDENV panel had a higher rate of cross-reactivity to ZIKV NS1 protein compared with the pDENV panel (26.0% vs. 0%, two-tailed Fisher's exact test, P=0.007). As a 259 comparison, WNV samples had anti-E antibodies cross-reactive to all six flaviviruses tested, anti-260 261 NS1 antibodies recognizing WNV and cross-reactive to DENV, ZIKV or YFV, and anti-prM antibodies recognizing WNV only (Figure 1(G), Table S2). We next examined two samples each 262 263 from the pZIKV and DENV+ZIKV panels. Anti-E antibodies cross-reactive to all six flaviviruses 264 tested and anti-NS1 antibodies to ZIKV with cross-reactivity to DENV (one to three serotypes) and YFV were observed in both panels. In contrast, anti-prM antibodies were found to recognize 265 ZIKV only in the pZIKV panel and recognize both ZIKV and DENV in the DENV+ZIKV panel, 266 267 as verified by long exposure (Figures 1(I) and 1(J), and data not shown). A similar trend was

observed in other samples of the pZIKV and DENV+ZIKV panels (Table S2). Table 1

summarizes different viral protein bands recognized in 189 samples from the seven panels.

Table 2 summarizes the sensitivity and specificity of antibodies recognizing different NS1 or

271 prM proteins to discriminate infection with DENV, ZIKV and WNV as well as vaccination with

272 YF-17D. The overall sensitivity of anti-NS1 antibodies ranged from 50% to 100%, and the

specificity 51.2% to 99.4%. In contrast, the overall sensitivity/specificity of anti-prM antibodies

was higher (91.7/96.4%, 91.7/99.2%, 88.9/98.3%, and 91.3/92.5% for DENV, ZIKV, WNV, and

275 YF-17D infection/vaccination, respectively), suggesting that anti-prM antibodies is a

serocomplex-specific marker for the four flavivirus serocomplexes tested.

277 Serosurveillance by testing samples from endemic countries

To further examine whether or not this assay can be used for serosurveillance in countries where 278 multiple flaviviruses are endemic and sympatric, we first tested 50 samples from a fever 279 surveillance program in the Philippines between 2018 and 2019. Most samples had anti-E 280 281 antibodies cross-reactive to all six flaviviruses, anti-NS1 antibodies to one to three DENV serotypes and/or ZIKV, and anti-prM antibodies to one to three DENV serotypes only, suggesting 282 previous DENV infection (Figure 2(A)). Other samples did not have anti-E, anti-NS1 or anti-prM 283 284 antibodies to DENV, ZIKV, WNV or YFV, suggesting that they were seronegative to these flaviviruses (Figure 2(E)). Three samples had anti-E antibodies cross-reactive to all six 285 286 flaviviruses, anti-NS1 antibodies to one to three DENV serotypes and YFV or ZIKV, and anti-287 prM antibodies to one to three DENV serotypes and YFV without cross-reactivity to ZIKV or WNV, suggesting previous DENV and YFV infections/vaccination (Figure 2(B)). Four samples 288 had anti-E antibodies cross-reactive to all six flaviviruses, anti-NS1 antibodies to one to three 289 290 DENV serotypes and ZIKV or YFV, and anti-prM antibodies to one to three DENV serotypes and

ZIKV without cross-reactivity to WNV or YFV, suggesting previous DENV and ZIKV infections 291 (Figure 2(D)), whereas one sample had anti-E antibodies to ZIKV with faint cross-reactivity to 292 293 DENV2, anti-NS1 antibodies to ZIKV with faint cross-reactivity to DENV4, and anti-prM antibodies to ZIKV only, suggesting pZIKV infection (Figure 2(C)). 294 The pattern of E and prM proteins recognized in Western blot analysis and the number/ 295 296 percentage of positive and total samples from the Philippines are summarized in Figures 2(F) and 2(G). Of the 50 participants, 28 (56%) had previous DENV infection, 4 (8%) previous DENV and 297 ZIKV infections, 1 (2%) previous ZIKV infection, 3 (6%) previous DENV and YFV 298 infections/vaccination, and 14 (28%) negatives to the four flaviviruses tested; altogether 35 (70%) 299 had previous DENV infection. We further tested with a previously reported IgG ELISA based on 300 DENV FL-mutated VLP, and found 35 (70%) were positive and 15 (30%) negative (Figure 2(H)); 301 this is consistent with the results of Western blot analysis. Comparing the Western blot analysis 302 and DENV FL-VLP IgG ELISA, which had a sensitivity/specificity of 100.0%/93.3%, the 303 304 positive, negative and overall agreements were all 1.0 with a kappa assessment of 1.0 (Figure 2(I)). 305 We next tested 48 samples from suspected Zika cases collected in Salvador, Brazil during the 306 307 early phase of the ZIKV outbreak between 2015 and 2016. Anti-E antibodies cross-reactive to all six flaviviruses and anti-NS1 antibodies recognizing one to three DENV serotypes and/or ZIKV 308 309 or YFV were found in all samples tested. Based on the recognition of anti-prM antibodies, we

found four patterns. Some samples recognized DENV prM protein of one to three serotypes

311 without cross-reactivity to ZIKV, YFV or WNV, suggesting previous DENV infection (Figure

312 3(A)), whereas others recognized DENV (one to three serotypes) and ZIKV or YFV prM proteins,

suggesting previous DENV and ZIKV infections (Figure 3(B)) or DENV and YFV

- 314 infections/vaccination (Figure 3(C)), respectively. Interestingly, some samples recognized DENV
- 315 (one to three serotypes), ZIKV and YFV prM proteins, suggesting previous DENV, ZIKV and
- 316 YFV infections/vaccination (Figure 3(D)).
- The pattern of E and prM proteins recognized in Western blot analysis and the
- number/percentage of positive and total samples from Brazil are summarized in Figures 3(E) and
- 319 3(F). Of the 48 participants, 11 (22.9%) had previous DENV infection, 8 (16.7%) previous DENV
- and ZIKV infections, 12 (25%) previous DENV and YFV infections/vaccination, and 17 (35.4%)
- 321 previous DENV, ZIKV and YFV infections/vaccination. Taken together, all participants (100%)
- had previous DENV infection, 52.1% (25/48) previous ZIKV infection, and 60.4% (29/48)
- 323 previous YFV infection or vaccination.

324 Discussion

In this study, we employed antigens of six flaviviruses from four serocomplexes in Western blot 325 analysis to test six panels of samples with well-documented flavivirus infections or vaccination 326 and found that anti-prM antibodies is a specific marker for four flavivirus serocomplexes with an 327 328 overall sensitivity/specificity of 91.7%/96.4%, 91.7%/99.2%, 88.9%/98.3%, and 91.3%/92.5%, for DENV, ZIKV, WNV, and YFV infections/vaccination, respectively. These findings have 329 implications for serodiagnosis and serosurveillance to further our understanding of the 330 331 epidemiology, transmission and immunopathogenesis in regions where multiple flaviviruses cocirculate. 332 In agreement with previous reports of cross-reactivities of flavivirus E proteins [24-27], anti-333 E antibodies were found to cross-react to all six flaviviruses (DENV1, 2 and 4, WNV, ZIKV and 334 YFV) tested in our control panels including pDENV, sDENV, pZIKV, DENV+ZIKV, WNV and 335 YF-17D panels, except that two NHPs and five participants receiving YF-17D vaccine 336 recognized YFV E protein only probably due to generally weak antibody response to live-337 attenuated vaccine or sampling time ≤ 2 months or >3-5 years after vaccination (Table S2). 338 339 Interestingly, anti-YFV prM antibodies were found in the majority (21/23) of YFV samples tested but only in few from other control panels with an overall sensitivity/specificity of 340 91.3%/92.5% (Tables 1 and 2). Consistent with our previous report, anti-prM antibodies can 341 342 discriminate DENV, ZIKV and WNV infections (36). Notably, anti-prM antibodies to one to three DENV serotype were detected in 22/25 of the DENV+ZIKV panel but in 2/23 of the 343 pZIKV panel (P<0.0001, two tailed Fisher exact test, Table 1), suggesting that anti-DENV prM 344 antibodies can distinguish these two panels. Although the sensitivities of anti-prM antibodies, 345 ranging from 88,9% (WNV) to 91.3%–91.7% (DENV, ZIKV and YFV) were moderate, the 346

specificities were high (92.5%-99.2%), which was most interesting given that low specificity has
been a concern for many serological tests for flaviviruses.

349 The overall sensitivity/specificity of anti-NS1 antibodies for DENV, ZIKV, WNV, and YFV infections/vaccination were 93.8/51.2%, 100/86.4%, 50.0/99.4%, and 95.7/70.8%, respectively, 350 351 suggesting that anti-NS1 antibody is not a specific marker for the four flavivirus serocomplexes 352 tested in our assay. Compared with ELISA, our previous study reported that detection of anti-NS1 antibodies in Western blot analysis was less specific, probably due to the presence of cross-353 reactive anti-NS1 antibodies that recognized linear epitopes in detergent-treated NS1 monomers 354 in Western blot analysis but not NS1 hexamers in solution such as in ELISA [36]. Within the 355 DENV serocomplex, we found that the sDENV panel had higher rates of detecting anti-prM and 356 anti-NS1 antibodies compared with the pDENV panel (98.0% vs. 81.0% and 98.0% vs. 76.2%, 357 respectively, P=0.02 and P=0.008, Fisher exact test, Table 1). Nonetheless, the difference was 358 insufficient to distinguish these two panels [24,36]. Of note, protein bands corresponding DENV 359 360 or YFV NS1 protein were recognized by some DENV-naive samples, however, none of the six flavivirus E proteins tested was recognized by these samples (Table 1), suggesting non-specific 361 362 binding to proteins present in these cell lysates.

The ZIKV outbreak in the Americas has drawn renewed interest in the epidemiology and transmission of ZIKV in other parts of the world (15). Several lines of evidence including documented Zika cases among travelers from Southeast Asia, retrospective analysis of archived samples, and enhanced surveillance suggested that ZIKV has been circulating at a low but sustained level in several countries in Southeast Asia including the Philippines [46-52]. Consistent with these reports, we found approximately 10% of the participants from the Philippines had previous ZIKV or ZIKV and DENV infections [51,52]. The DENV detection rate of 70% among

the participants (aged 2–56 years) was generally in agreement with the seroprevalence rate 370 estimated previously [53]. When testing with 48 samples of suspected Zika cases collected 371 372 between November 2015 and June 2016 in Salvador, we found that all participants (100%) had previous DENV infection and 52.1% (25/48) had previous DENV and ZIKV infections, which 373 was generally in agreement with previous reports of ZIKV seroprevalence during the early phase 374 375 of ZIKV outbreak in the Northeastern Brazil [54,55]. It is worth noting that the recent YFV outbreak in the Southeastern Brazil started in November 2016, when deaths of NHPs due to YFV 376 377 infection was reported, followed by human cases since December 2016 with a total of 2237 cases as of June 2019 [10,56,57]; thus, detection of anti-YFV prM antibodies in our participants was 378 unlikely due to the recent YFV outbreak. Our findings that 60.4% (29/48) of participants (aged 379 15-63 years) had anti-YFV prM antibodies was consistent with the estimated coverage rate of YF 380 vaccination in Brazil (30–70% for individuals aged 15–70 years) and suggested they had previous 381 YF-17D vaccination [58]. Nonetheless, the possibility of exposure during previous YFV 382 383 outbreaks (2000-2001 and 2008-2009) in the Southeastern and Northeastern states of Brazil cannot be completed ruled out [10,56,57]. 384

Although different neutralization tests including PRNTs, focus reduction neutralization, 385 386 microneutralization test, reporter viruses, and flow-based neutralization tests, have been developed for flaviviruses, the requirement of labor-intensive work, trained staff, equipment and 387 388 appropriate biocontainment has limited their applications to reference or research laboratories. 389 Compared with PRNTs, our Western blot analysis is faster (18 h for six viral antigens vs. 5-6 390 days for PRNTs for each virus), and requires less sample volume (5 μ L vs. 128 μ L for PRNTs 391 for six antigens or viruses). Moreover, the half-membrane employed in our Western blot analysis 392 can be prepared in advance, stored in a -20°C freezer, and hybridized to serum/plasma up to four

393	months with comparable results (Figure S1), supporting potential application in regional
394	laboratories. It can also be prepared in strips for use as a simple, inexpensive and readily
395	applicable diagnostic test, as exemplified by the first-generation HIV immunoassay [59].
396	One major challenge of PRNT is that it cannot discriminate multiple flavivirus infections
397	experienced in the past, thus restricting its application for serosurveillance in flavivirus-endemic
398	regions. Despite a previous study reporting different cross-neutralization patterns observed in
399	various ZIKV and DENV infections, whether a defined neutralizing antibody titer (PRNT50 titer)
400	can discriminate sDENV and DENV+ZIKV panels or it can be applied to regions where other
401	flaviviruses (YFV, WNV or JEV) are prevalent remains unclear [60]. A recent study in
402	Indonesian Archipelago, a DENV hyperendemic region, revealed multitypic neutralizing
403	antibodies to two or more DENV serotypes and suggested possible ZIKV circulation based on
404	high stringent PRNT90 titers, underscoring the difficulty of using PRNT to delineate DENV and
405	ZIKV infections in hyperendemic regions [61]. Other studies used two-step neutralization tests
406	(initial screening by PRNT to ZIKV followed by PRNT to DENV1-4 and ZIKV) [48,49] or
407	combination of IgG ELISA and neutralization test (for positive or equivocal samples) to
408	investigate ZIKV or DENV seroprevalence in endemic regions [62-64]. However, the
409	interpretation of multitypic neutralizing antibody profile remains a challenge.
410	Our assay using a half membrane with six flavivirus antigens to detect IgG in Western blot
411	analysis can be combined with IgG ELISA to verify those positive or equivocal samples and
412	provide detailed information of infections/exposure of four flavivirus serocomplexes in the past.
413	Given the high specificities of anti-prM antibodies (92.5%-99.2%) in our assay, combination of
414	our assay with other serological tests is unlikely to reduce the overall specificity. Our assay has
415	several potential applications, such as determining flavivirus immune background of participants

in a vaccine trial or a seroepidemiological study in endemic regions, and confirming infections
with the four flavivirus serocomplexes during surveillance. Our assay can also be employed in
retrospective studies of pregnant women with CZS or normal babies to investigate the influence
of different ZIKV, DENV, YFV, and/or WNV immune status on pregnancy outcomes. These
together would improve our understanding of the epidemiology, immunopathogenesis and
complications of ZIKV and DENV in flavivirus-endemic regions.

There were several limitations of this study. First, the sample size in each panel of well-422 documented flavivirus infections or YF-17D vaccination was relatively small; future studies with 423 larger sample size are warranted to validate these observations. Second, although samples were 424 collected from four months to 31 years after pDENV or sDENV infection and from two months 425 to five years after YF-17D vaccination, samples with longer duration following other flavivirus 426 infections such as ZIKV, DENV+ZIKV and WNV are needed to verify these observations. 427 Third, anti-YFV prM antibodies cannot distinguish YFV natural infection and vaccination with 428 429 YF-17D, a live-attenuated vaccine. Similarly, anti-DENV prM antibodies cannot discriminate DENV natural infection and vaccinees who received live-attenuated DENV vaccines. Given the 430 availability of other flavivirus vaccines including JEV and tick-borne encephalitis virus vaccines 431 432 and several ongoing vaccines trials in endemic regions, serological tests that can distinguish flavivirus natural infection and vaccination remain to be exploited in future studies [65,66]. 433

434	Ackn	owled	dgments
-----	------	-------	---------

435	We thank Drs. E. Harris at the University of California Berkeley and A. Balmaseda at the
436	Ministry of Health, Managua, Nicaragua for providing samples from Nicaragua, S. L. Stramer at
437	the American Red Cross at Gaithersburg, Maryland for providing samples from blood donors,
438	GJ. Chang at the Center for Disease Control and Prevention at Fort Collins for providing the
439	plasmid expressing YF-17D prM/E proteins, Colorado, and S. Verma at the John A. Burns
440	School of Medicine, University of Hawaii at Manoa for providing WNV-infected cell lysates.
441	
442	Disclosure Statement
443	No potential conflict of interest was reported by the authors.
444	
445	Funding
446	This work was supported by grants R01AI149502 (WKW) from the National Institute of Allergy
447	and Infectious Diseases, National Institutes of Health (NIH); P20GM130448 (YSH) from the
448	National Institute of General Medical Sciences, NIH; MedRes-2022-0000 0789 (WKW) from the
449	Hawaii Community Foundation; Grant (AKS, MJ) from the Philippine Council for Health
450	Research and Development; MOHW109-TDU-B-212-114006 (JJT) and MOHW110-TDU-B-
451	212-124006 (JJT) from the Ministry of Health and Welfare, Taiwan; and NHRI-110A1-MRCO-
452	03212101 (JJT) from the National Health Research Institute, Taiwan; Grant 404193/2019-6
453	(EMN) from the Brazilian National Council for Scientific and Technological Development
454	(CNPq). The funders had no role in study design, data collection and analysis, decision to
455	publish, or preparation of the manuscript. The content is solely the responsibility of the authors
456	and does not represent the official views of the NIH.

457

458 **Author contributions**

- 459 GHC, YCD and WKW contributed to study design. GHC, YCD and SZH conducted the
- 460 experiments. GHC, YCD and WKW performed the data analysis. GHC, YCD and WKW had
- 461 access to underlying data. JJT, AKS, MJ, CP, CB, EMN, PJK, DRDS, DLV, SH, YSH and
- 462 WKW contributed to reagent or sample collection and funding acquisition. GHC, YCD and
- 463 WKW contributed to manuscript writing. All authors contributed to the article and approved the
- 464 submitted version.
- 465

466 **Supplemental Materials**

- 467 Table S1 and S2
- 468 Figure S1

469 **References**

- 1. Pierson TC, Diamond MS. 2013. Flaviviruses. Knipe DM, Howley PM, eds. Fields virology,
- 6th ed, Philadelphia: Lippincott William & Wilkins. pp 747-794.
- 472 2. Guzman MG, Harris E. Dengue. Lancet. 2015;385:453-465.
- 3. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature.
 2013;496:504-507.
- 475 4. World Health Organization. Dengue and severe dengue. https://www.who.int/news476 room/fact-sheets/detail/dengue-and-severe-dengue
- 5. Halstead SB, Dans LF. Dengue infection and advances in dengue vaccines for children.
- 478 Lancet Child Adolesc Health. 2019;3:734-741.
- 479 6. WHO. Dengue vaccine: WHO position paper September 2018. Weekly Epidemiological
 480 Record. 2018;93:457-476.
- 7. Sridhar S, Luedtke A, Langevin E, et al. Effect of dengue serostatus on dengue vaccine
 safety and efficacy. N Engl J Med. 2018;379:327-340.
- 483 8. Wilder-Smith A, Smith PG, Luo R, et al. Pre-vaccination screening strategies for the use of
 484 the CYD-TDV dengue vaccine: A meeting report. Vaccine. 2019;37:5137-5146.
- 485 9. Chen LH, Wilson ME. Yellow fever control: current epidemiology and vaccination
 486 strategies. Trop Dis Travel Med Vaccines. 2020;6:1.
- 10. de Oliveira Figueiredo P, Stoffella-Dutra AG, Barbosa Costa G, et al. Re-emergence of
- 488 yellow fever in Brazil during 2016-2019: challenges, lessons learned, and perspectives.
- 489 Viruses. 2020;12:1233.
- 490 11. Girard M, Nelson CB, Picot V, et al. Arboviruses: A global public health threat. Vaccine.
 491 2020;38:3989-3994.
- 492 12. Jani C, Kakoullis L, Abdallah N, et al. West Nile virus: another emerging arboviral risk for

- 493 travelers? Curr Infect Dis Rep. 2022;24:117-128.
- 494 13. Lessler J, Chaisson LH, Kucirka LM, et al. Assessing the global threat from Zika virus.

495 Science. 2016;353:aaf8160.

- 496 14. PAHO, Regional Zika epidemiological update (Americas) 25 August 2017 [accessed Dec.
- 497 1, 2020]. available from:
- 498 http://www.paho.org/hq/index.php?option=com_content&view=article&id=11599&Itemid
 499 =41691&lang=en
- 500 15. Musso D, Ko AI, Baud D. Zika virus infection after the pandemic. N Engl J Med.
- 501 2019;381:1444-1457.
- 502 16. Anderson KB, Gibbons RV, Thomas SJ, et al. Preexisting Japanese encephalitis virus
- neutralizing antibodies and increased symptomatic dengue illness in a school-based cohort
 in Thailand. PLoS Negl Trop Dis. 2011;5:e1311.
- 505 17. Rodriguez-Barraquer I, Costa F, Nascimento EJM, et al. Impact of preexisting dengue
- immunity on Zika virus emergence in a dengue endemic region. Science. 2019;363:607-
- 507 610.
- 508 18. Gordon A, Gresh L, Ojeda S, et al. Prior dengue virus infection and risk of Zika: A pediatric
 509 cohort in Nicaragua. PLoS Med. 2019;16:e1002726.
- 510 19. Katzelnick LC, Narvaez C, Arguello S, et al. Zika virus infection enhances future risk of
 511 severe dengue disease. Science. 2020;369:1123-8.
- 512 20. Tsai WY, Lin HE, Wang WK. Complexity of human antibody response to dengue virus:
- 513 implication for vaccine development. Front Microbiol. 2017;8:1372.
- 514 21. Martin DA, Muth DA, Brown T, et al. 2000. Standardization of immunoglobulin M capture
- enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J Clin

516 Microbiol. 2000;38:1823-1826.

517 22. Johnson AJ, Martin DA, Karabatsos N, et al. Detection of anti-arboviral immunoglobulin G

518 by using a monoclonal antibody-based capture enzyme-linked immunosorbent assay. J Clin

519 Microbiol. 2000;38:1827-1831.

520 23. Guidance for U.S. Laboratories testing for Zika virus infection. From CDC's website:

521 http://www.cdc.gov/zika/laboratories/lab-guidance.html.

522 24. Lai CY, Tsai WY, Lin SR, et al. Antibodies to envelope glycoprotein of dengue virus during

523 the natural course of infection are predominantly cross-reactive and recognize epitopes

524 containing highly conserved residues at the fusion loop of domain II. J Virol. 2008;82:6631-

525 6643**.**

526 25. Lanciotti RS, Kosoy OL, Laven JJ, et al. Genetic and serologic properties of Zika virus
527 associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis. 2008;14:1232528 1239.

26. Johnson BW, Kosoy O, Martin DA, et al. West Nile virus infection and serologic response

among persons previously vaccinated against yellow fever and Japanese encephalitis

viruses. Vector Borne Zoonotic Dis. 2005;5:137-145.

532 27. Felix AC, Souza NCS, Figueiredo WM, et al. Cross reactivity of commercial anti-dengue

immunoassays in patients with acute Zika virus infection. J Med Virol. 2017;89:1477-1479.

28. Steinhagen K, Probst C, Radzimski C, et al. Serodiagnosis of Zika virus (ZIKV) infections

by a novel NS1-based ELISA devoid of cross-reactivity with dengue virus antibodies: a

536 multicohort study of assay performance, 2015 to 2016. Euro Surveill. 2016;21:30426.

537 29. Safronetz D, Sloan A, Stein DR, et al. Evaluation of 5 commercially available Zika virus

immunoassays. Emerg Infect Dis. 2017;23:1577-1580.

539	30. Balmaseda A, Zambrana JV, Collado D, et al. Comparison of four serological methods and
540	two reverse transcription-PCR assays for diagnosis and surveillance of Zika virus infection.
541	J Clin Microbiol. 2018;56:e01785-17.

- 542 31. Tsai WY, Youn HH, Brites C, et al. Distinguishing secondary dengue virus infection from
- 543 Zika virus infection with previous dengue by combination of three simple serological tests.
- 544 Clin Infect Dis. 2017;65:1829-1836.
- 545 32. Tyson J, Tsai WY, Tsai JJ, et al. A high-throughput and multiplex microsphere
- 546 immunoassay based on non-structural protein 1 can discriminate three flavivirus infections.
- 547 PLoS Negl Trop Dis. 2019; 13:e0007649.
- 548 33. Innis BL. 1997. Antibody responses to dengue virus infection. In Gubler DJ, Kuno G eds:
- 549 Dengue and dengue hemorrhagic fever. Cambridge, MA: CAB International, pp. 221-244.
- 550 34. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv.
- 551 Virus Res. 2003;60:421-467.
- 552 35. Alvarez M, Rodriguez-Roche R, Bernardo L, et al. Dengue hemorrhagic Fever caused by
- sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-
- 554 2002. Am J Trop Med Hyg. 2006;75:1113-1117.
- 555 36. Hsieh SC, Tsai WY, Tsai JJ, et al. Identification of anti-premembrane antibody as a
- serocomplex-specific marker to discriminate Zika, dengue, and West Nile virus infections. J
 Virol. 2021;95:e0061921.
- 558 37. Kuan G, Gordon A, Avilés W, et al. The Nicaraguan pediatric dengue cohort study: study
- design, methods, use of information technology, and extension to other infectious diseases.
- 560 Am J Epidemiol. 2009;170:120-129.
- 38. NarvaezF, Gutierrez G, Perez MA, et al. Evaluation of the Traditional and revised WHO

562	classifications of dengue disease severity. PLoS Negl Trop Dis. 2011;5:e1397.
563	39. Herrera BB, Tsai WY, Brites C, et al. T cell responses to nonstructural protein 3 distinguish
564	infections by dengue and Zika viruses. mBio. 2018;9: e00755-18.
565	40. Tyson J, Tsai WY, Tsai JJ, et al. Combination of non-structural protein 1-based enzyme-
566	linked immunosorbent assays can detect and distinguish various dengue virus and Zika
567	virus infections. J Clin Microbiol. 2019;57:e01464-18.
568	41. Tsai JJ, Liu CK, Tsai WY, et al. Seroprevalence of dengue in two districts of Kaohsiung city
569	after the largest dengue outbreak in Taiwan since world war II. PLoS Negl Trop Dis.
570	2018;12: e0006879
571	42. Tsai WY, Chen HL, Tsai JJ, et al. Potent neutralizing human monoclonal antibodies
572	preferentially target mature dengue virus particles: implication for novel strategy of dengue
573	vaccine. J Virol. 2018;92:e00556-18.
574	43. Dai YC, Sy AK, Jiz M, et al. Identification of prior dengue-naïve Dengvaxia recipients with
575	an increased risk for symptomatic dengue during fever surveillance in the Philippines. Front
576	Immunol 2023;14:1202055.
577	44. Tsai WY, Driesse K, Tsai JJ, et al. Enzyme-linked immunosorbent assays using virus-like
578	particles containing mutations of conserved residues on envelop protein can distinguish three
579	flavivirus infections. Emerg Microbe Infect. 2020;9:1722-1732.
580	45. Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination
581	method for immunoassays. J. Immunol. Methods. 1998;221:35-41.
582	46. Duong V, Dussart P, Buchy P. Zika virus in Asia. Int J Infect Dis. 2017;54:121-128.
583	47. Sasmono RT, Dhenni R, Yohan B, et al. Zika virus seropositivity in 1-4-year-old children,
584	Indonesia, 2014. Emerg Infect Dis. 2018;24:1740-1743.

- 48. Sasmono RT, Johar E, Yohan B, et al. Spatiotemporal heterogeneity
- of Zika virus transmission in Indonesia: serosurveillance data from a pediatric population.
- 587 Am J Trop Med Hyg. 2021;104:2220-2223.
- 49. Pastorino B, Sengvilaipaseuth O, Chanthongthip A, et al. Low Zika virus seroprevalence in
- 589 Vientiane, Laos, 2003-2015. Am J Trop Med Hyg. 2019;100:639-642.
- 590 50. Ruchusatsawat K, Wongjaroen P, Posanacharoen A, et al. Long-term circulation
- of Zika virus in Thailand: an observational study. Lancet Infect Dis. 2019;19:439-446.
- 592 51. Biggs JR, Sy AK, Brady OJ, et al. Serological evidence of widespread Zika transmission
- across the Philippines. Viruses. 2021;13:1441.
- 594 52. Lonogan K. de Guzman A, Delos Reyes VC, et al. The enhanced Zika surveillance in the

Philippines, November 14, 2016–February 28, 2017. Int J Infect Dis. 2020, 101;232–233.

596 53. L'Azou M, Moureau A, Sarti E, et al. Symptomatic Dengue in Children in 10 Asian and

Latin American Countries. N Engl J Med. 2016;374:1155-1166.

- 598 54. Netto EM, Moreira-Soto A, Pedroso C, et al. High Zika virus seroprevalence in Salvador,
- 599 Northeastern Brazil limits the potential for further outbreaks. MBio. 2017;8 e01390-17.
- 600 55. Alves LV, Leal CA, Alves JGB. Zika virus seroprevalence in women who gave birth

during Zika virus outbreak in Brazil - a prospective observational study. Heliyon.

602 2020;6:e04817.

- 56. Rezende IM, Sacchetto L, Munhoz de Mello É, et al. Persistence of yellow fever virus
- outside the Amazon Basin, causing epidemics in Southeast Brazil, from 2016 to 2018.PLoS
 Negl Trop Dis. 2018;12:e0006538.
- 57. Dexheimer Paploski IA, Souza RL, Tauro LB, et al. Epizootic outbreak of yellow fever virus
- and risk for human disease in Salvador, Brazil. Ann Intern Med. 2018;168:301-302.

608	58. Shearer FM, Moyes CL, Pigott DM, et al. Global yellow fever vaccination coverage from
609	1970 to 2016: an adjusted retrospective analysis. Lancet Infect Dis. 2017;17:1209-17.
610	59. Centers for Disease Control and Prevention and Association of Public Health Laboratories.
611	Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. 2014.
612	http://stacks.cdc.gov/view/cdc/23447.
613	60. Montoya M, Collins M, Dejnirattisai W, et al. Longitudinal analysis of antibody cross-
614	neutralization following Zika virus and dengue virus infection in Asia and the Americas. J
615	Infect Dis. 2018;218:536-545.
616	61. Harapan H, Panta K, Michie A, et al. Hyperendemic dengue and possible Zika circulation in
617	the westernmost region of the Indonesian Archipelago. Viruses. 2022;14:219.
618	62. Nurtop E, Villarroel PMS, Pastorino B, et al. Combination of ELISA screening and
619	seroneutralisation tests to expedite Zika virus seroprevalence studies. Virol J. 2018;15:192.
620	63. Saba Villarroel PM, Nurtop E, Pastorino B, et al. Zika virus epidemiology in Bolivia: A
621	seroprevalence study in volunteer blood donors. PLoS Negl Trop Dis. 2018;12:e0006239.
622	64. Lopez AL, Adams C, Ylade M, et al. Determining dengue virus serostatus by indirect IgG
623	ELISA compared with focus reduction neutralisation test in children in Cebu, Philippines: a
624	prospective population-based study. Lancet Glob Health. 2021;9:e44-e51.
625	65. Simmons G, Stone M, Busch MP. 2018. Arbovirus diagnostics: from bad to worse due to
626	expanding dengue virus vaccination and Zika virus epidemics. Clin Infect Dis. 2018;
627	66:1181-13.
628	66. Munoz-Jordan JL. Diagnosis of Zika virus infections: challenges and opportunities. J Infect
629	Dis. 2017;216:S951-S956.

630 Figure Legends

Figure 1. Antibody response to six flavivirus antigens following YF-17D vaccination or DENV,

632 ZIKV or WNV infection. Lysates derived from mock-, DENV1-, DENV2-, DENV4-, WNV-,

- 633 ZIKV-, and YFV (17D strain)-infected Vero cells were subjected to SDS-12% polyacrylamide
- 634 gel electrophoresis under non-reducing condition and Western blot analysis probed with different
- 635 serum/plasma samples or anti-E mouse mAb FL0232 (C). Results of YF-17D vaccinees (A) and
- 636 NHPs receiving YF-17D vaccine (D), DENV-naïve participant (E), and participants with pDENV
- 637 (F), WNV (G), sDENV (H), pZIKV (I), and DENV+ZIKV (D+ZK) (J) infections. Lysates
- derived from 293T cells transfected with YF-17D prM/E plasmid were subjected to Western blot
- analysis and probed with a DENV- and YFV-immune serum, short (left) and long (right)
- exposure (B). The sampling time post-symptom onset, vaccination or TMA test was indicated
- after sample ID. pDENV, primary DENV infection; sDENV, secondary DENV infection;
- 642 pZIKV, primary ZIKV infection. The positions of E, NS1 and prM protein bands are indicated.
- The size of molecular weight markers is shown in kDa. Mo: mock, D1: DENV1, D2: DENV2,

644 D4: DENV4, WN: WNV, ZK: ZIKV, and YF: YF-17D.

645

Figure 2. Antibody response to six flavivirus antigens in samples from a fever surveillance
program in the Philippines. (A-E) Results of participants with previous DENV infection (A),
previous DENV and YFV infections/vaccination (D+YF) (B), pZIKV infection (C), previous
DENV and ZIKV infections (D+ZK) (D), and seronegative to DENV, ZIKV, YFV and WNV
(Neg) (E). The positions of E, NS1 and prM protein bands are indicated. The size of molecular
weight markers is shown in kDa. Mo: mock, D1: DENV1, D2: DENV2, D4: DENV4, WN:
WNV, ZK: ZIKV, and YF: YF-17D. (F,G) The pattern of E and prM proteins recognized and the

653	number/percentage of positive and total samples based on Western blot analysis (F) and a graphic
654	summary (G). (H,I) Results of DENV FL-VLP IgG ELISA (H) and comparison with that of anti-
655	DENV prM reactivity in Western blot analysis (I). rOD: the relative OD. The two-tailed Mann-
656	Whitney test was performed in panel H.
657	
658	Figure 3. Antibody response to six flavivirus antigens in samples from suspected ZIKV cased
659	during the ZIKV outbreak in Brazil. (A-D) Results of participants with previous DENV infection
660	(A), previous DENV and ZIKV infections (D+ZK) (B) previous DENV and YFV
661	infections/vaccination (D+YF) (C), and previous DENV, ZIKV and YFV infections/vaccination
662	(D+ZK+YF) (D). The positions of E, NS1 and prM protein bands are indicated. The size of
663	molecular weight markers is shown in kDa. Mo: mock, D1: DENV1, D2: DENV2, D4: DENV4,
664	WN: WNV, ZK: ZIKV, and YF: YF-17D. (E,F) The pattern of E and prM proteins recognized
665	and the number/percentage of positive and total samples based on Western blot analysis (E) and a
666	graphic summary (F).



Е

NS1

prM

Е

NS1

prM

NS1

prM

Е

NS1

prM

Е

NS1

prM



ŀ	-	

		-	-
	E and prM proteins recognized in WB analysis	No. of positive /total (%)	Interpretation
	D1, D2 or D4 prM+, all E+	28/50 (56%)	DENV
Ī	D1, D2 or D4 prM+, ZIKV prM+, all E+	4/50 (8%)	DENV+ZIKV
	D1, D2 or D4 prM−, ZIKV prM+, Z E+	1/50 (2%)	pZIKV
	D1, D2 or D4 prM+, YFV prM+, all E+	3/50 (6%)	DENV+YFV
	D1, D2 or D4 prM-, ZIKV prM-, YFV prM-, all E-	14/50 (28%)	negative



D,ZK,YF,WN negative=14





		DENV FL-VLP IgG ELISA		
		pos	neg	total
anti-DENV prM in WB	pos	35	0	35
	neg	0	15	15
	total	35	15	50
positive agreement=1.0 overall agreement=1.0				
negative agreement=1.0 kappa assessment=1.0				



		-
E and prM proteins recognized in WB analysis	No. of positive /total (%)	Interpretation
D1, D2 or D4 prM+, all E+	11/48 (22.9%)	DENV
D1, D2 or D4 prM+, ZIKV prM+, all E+	8/48 (16.7%)	DENV+ZIKV
D1, D2 or D4 prM+, YFV prM+, all E+	12/48 (25.0%)	DENV+YFV
D1, D2 or D4 prM+, ZIKV prM+, YFV prM+, all E+	17/48 (35.4%)	DENV+ZIKV+YFV
D1, D2 or D4 prM-, ZIKV prM-, YFV prM-, all E-	0/48 (0%)	negative



D,ZK,YF,WN negative=0

	No. of positive/total samples (%) in different serum/plasma panels						
Protein bands recognized ^{c,d}	DENV- naive	pDENV	sDENV	pZIKV	DENV+ZIKV	WNV ^b	YF-17D
D1, D2 or D4 NS1	6/29	16/21	49/50	20/23	25/25	14/18	1/14 ^g
	(20.7%)	(76.2%)	(98.0%)	(87.9%)	(100%)	(77.8%)	(7.1%)
ZIKV NS1	0/29	0/21	13/50	23/23	25/25	5/18	0/14 ^g
	(0%)	(0%)	(26.0%)	(100%)	(100%)	(27.8%)	(0%)
WNV NS1	0/29	0/21	0/50	0/23	1/25	9/18	0/23
	(0%)	(0%)	(0%)	(0%)	(4.0%)	(50.0%)	(0%)
YFV NS1	7/29 (24.1%)	5/17 ^f (29.4%)	6/29 ^f (20.7%)	3/18 ^f (16.7%)	10/13 ^f (76.9%)	NA ^e	22/23 (95.7%)
D1, D2 or D4 prM	0/29	17/21	49/50	2/23	22/25	0/18	1/14 ^g
	(0%)	(81.0%)	(98.0%)	(8.7%)	(88.0%)	(0%)	(7.1%)
ZIKV prM	0/29	0/21	1/50	23/23	21//25	0/18	0/14 ^g
	(0%)	(0%)	(2.0%)	(100%)	(84.0%)	(0%)	(0%)
WNV prM	0/29	0/21	0/50	0/23	3/25	16/18	0/23
	(0%)	(0%)	(0%)	(0%)	(12.0%)	(88.9%)	(0%)
YFV prM	1/29 (3.4%)	1/17 ^f (5.9%)	2/29 ^f (6.9%)	2/18 ^f (11.1%)	2/13 ^f (15.4%)	NA ^e	21/23 (91.3%)
any E (D1, D2, D4,	0/29	21/21	50/50	23/23	25/25	18/18	23/23
ZIKV, WNV or YFV)	(0%)	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)

Table 1. Summary of viral proteins recognized by different panels^a in Western blot analysis

^apDENV, primary DENV infection; sDENV, secondary DENV infection; pZIKV, primary ZIKV infection; DENV+ZIKV, previous DENV and ZIKV infections; WNV, WNV infection; YF-17D, YF-17D vaccination.

^bIndex samples tested positive for WNV transcription-mediated amplification, IgM and IgG from blood donors at the American Red Cross [40].

^cNS1, nonstructural protein 1; prM, premembrane; D1, DENV1; D2, DENV2; D4, DENV4.

 $^dNo.~(\%)$ of homologous prM and NS1 proteins recognized by each panel are bolded.

^eNA, not applicable; the history of YF-17D vaccination was not available in this panel. ^fDue to the lack of history of YF-17D vaccination or infection from a subset of the pDENV (n=4), sDENV (n=21), pZIKV (n=5) and DENV+ZIKV (n=12) panels from Brazil, these samples were not

included in the analysis of YFV NS1 or prM recognition.

^gDue to the lack of history of DENV or ZIKV infection from a subset of the YF-17D (n=9) panel from Brazil, these samples were not included in the analysis of DENV and ZIKV NS1 or prM recognition.

	7 1		9
Viral proteins recognized ^c	Group	% Sensitivity (95% CI) ^{a,b}	% Specificity (95% CI) ^{a,b}
D1, D2 or D4 NS1	overall	93.8 (88.9–96.2)	51.2 (40.5–56.6)
	subgroup	pDENV:76.2, sDENV:98.0, DENV+ZIKV:100	DENV-naive:79.3, pZIKV:87.0, WNV:22.2, YF-17D:92.9
ZIKV NS1	overall	100 (100–100)	86.4 (80.5–89.4)
	subgroup	pZIKV:100, DENV+ZIKV:100	DENV-naive:100, pDENV:100, sDENV:74.0, WNV:72.2, YF-17D:100
WNV NS1	overall	50.0 (26.9–61.8)	99.4 (98.3–100)
	subgroup	WNV:50.0	DENV-naive:100, pDENV:100, sDENV:100, pZIKV:100, DENV+ZIKV:96.0, YF-17D:100
YFV NS1	overall	95.7 (87.3–99.9)	70.8 (62.1–75.2)
	subgroup	YF17D:95.7	DENV-naive:75.9, pDENV:70.6, sDENV:79.3, pZIKV:83.3, DENV+ZIKV:23.1, WNV:NA ^e
D1, D2 or D4 prM	overall	91.7 (86.1–94.5) ^d	96.4 (92.5–98.5) ^d
	subgroup	pDENV:81.0, sDENV:98.0, DENV+ZIKV:88.0	DENV-naive:100, pZIKV:91.3, WNV:100, YF-17D:92.9
ZIKV prM	overall	91.7 (83.9–95.7) ^d	99.2 (97.8–100) ^d
	subgroup	pZIKV:100, DENV+ZIKV:84.0	DENV-naive:100, pDENV:100, sDENV:98.0, WNV:100, YF-17D:100
WNV prM	overall	88.9 (74.4–96.3) ^d	98.3 (96.3–99.3) ^d
	subgroup	pWNV:88.9	DENV-naive:100, pDENV:100, sDENV:100, pZIKV:100, DENV+ZIKV:88.0, YF-17D:100
YFV prM	overall	91.3 (79.8–97.2) ^d	92.5 (87.4–95.0) ^d
	subgroup	YF17D:91.3	DENV-naive:96.6, pDENV:94.1, sDENV:93.1, pZIKV:88.9, DENV+ZIKV:84.6, WNV:NA ^e

Table 2. Sensitivity and	d specificity of vira	proteins recognized b	v different panels in	n Western blot analysis
--------------------------	-----------------------	-----------------------	-----------------------	-------------------------

^aCI, confidence interval. pDENV, primary DENV infection; sDENV, secondary DENV infection; pZIKV, primary ZIKV infection; DENV+ZIKV, previous DENV and ZIKV infections; WNV, WNV infection; YF-17D, YF-17D vaccination. ^bFor simplicity, the 95% CIs in the subgroup are not shown.

^oNS1, nonstructural protein 1; prM, premembrane; D1, DENV1; D2, DENV2; D4, DENV4.

^dThe sensitivity and specificity of recognizing prM protein are bolded. ^eNA, not applicable; the history of YF-17D vaccination was not available in this panel.